# [68Ga]DOTATATE-PET/MRI in Hepatocellular Carcinoma

> **NCT03648073** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Alabama at Birmingham** · enrollment: 12 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** [68Ga]DOTATATE-PET/MRI

## Key facts

- **NCT ID:** NCT03648073
- **Lead sponsor:** University of Alabama at Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-30
- **Primary completion:** 2022-02-03
- **Final completion:** 2022-02-03
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2023-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03648073

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03648073, "[68Ga]DOTATATE-PET/MRI in Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03648073. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*